Literature DB >> 16475049

Managing oral anticoagulation requires expert experience and clinical evidence.

Alex C Spyropoulos1.   

Abstract

The management of patients on chronic oral anticoagulant therapy, namely Vitamin K antagonists such as warfarin, is often associated with difficult and challenging issues for the healthcare practitioner. Many of these issues, such as warfarin failure or resistance, the optimal warfarin initiation dose, the optimal target International Normalized Ratio in antiphospholipid syndrome, the optimal monitoring frequency and use of point-of-care monitoring, the management of oral anticoagulation during invasive procedures, and the management of over-anticoagulation, have not been evaluated in rigorously-designed clinical trials. The latest American College of Chest Physician recommendations concerning these issues are Grade 2C, the weakest recommendations available. It remains up to the experience and expertise of the individual practitioner along with whatever clinical evidence is available in a particular healthcare environment-especially one associated with an anticoagulant management service-to implement management strategies with respect to these issues in patients on oral anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16475049     DOI: 10.1007/s11239-006-5583-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  20 in total

1.  A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.

Authors:  Mark A Crowther; Jeff S Ginsberg; Jim Julian; Judah Denburg; Jack Hirsh; James Douketis; Carl Laskin; Paul Fortin; David Anderson; Clive Kearon; Ann Clarke; William Geerts; Melissa Forgie; David Green; Lorrie Costantini; Wendy Yacura; Sarah Wilson; Michael Gent; Michael J Kovacs
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

2.  Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Gordon Guyatt; Holger J Schünemann; Deborah Cook; Roman Jaeschke; Stephen Pauker
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 3.  Perioperative bridging therapy for the at-risk patient on chronic anticoagulation.

Authors:  Alex C Spyropoulos
Journal:  Dis Mon       Date:  2005 Feb-Mar       Impact factor: 3.800

4.  A randomized trial comparing 5-mg and 10-mg warfarin loading doses.

Authors:  M A Crowther; J B Ginsberg; C Kearon; L Harrison; J Johnson; M P Massicotte; J Hirsh
Journal:  Arch Intern Med       Date:  1999-01-11

5.  Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption.

Authors:  Alex C Spyropoulos; Kimberly A Hayth; Patricia Jenkins
Journal:  Pharmacotherapy       Date:  2003-04       Impact factor: 4.705

6.  Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial.

Authors:  M A Crowther; J Julian; D McCarty; J Douketis; M Kovacs; L Biagoni; T Schnurr; J McGinnis; M Gent; J Hirsh; J Ginsberg
Journal:  Lancet       Date:  2000-11-04       Impact factor: 79.321

7.  Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study.

Authors:  Joseph Menzin; Luke Boulanger; Ole Hauch; Mark Friedman; Cheryl Beadle Marple; Gail Wygant; Judith S Hurley; Stephen Pezzella; Scott Kaatz
Journal:  Ann Pharmacother       Date:  2005-02-08       Impact factor: 3.154

Review 8.  Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Gregory W Albers; Pierre Amarenco; J Donald Easton; Ralph L Sacco; Philip Teal
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

9.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

10.  Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

Authors:  Michael J Kovacs; Marc Rodger; David R Anderson; Beverly Morrow; Gertrude Kells; Judy Kovacs; Eleanor Boyle; Philip S Wells
Journal:  Ann Intern Med       Date:  2003-05-06       Impact factor: 25.391

View more
  2 in total

1.  Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.

Authors:  Xia Zhao; Peihong Sun; Ying Zhou; Yuwang Liu; Huilin Zhang; Wolfgang Mueck; Dagmar Kubitza; Richard J Bauer; Hong Zhang; Yimin Cui
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

2.  Venous thromboembolism: classification, risk factors, diagnosis, and management.

Authors:  Fatemeh Moheimani; Denise E Jackson
Journal:  ISRN Hematol       Date:  2011-10-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.